Ada Y. Leung
Vancouver, BC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
A novel liposomal formulation of irinotecan comprising a combination of copper complexation and a transmembrane pH gradient to significantly improve irinotecan encapsulation and retention.
Journal: International journal of pharmaceutics
Published: January 30, 2026
Liposomal delivery of a disulfiram metabolite drives copper-mediated tumor immunity.
Journal: International journal of pharmaceutics
Published: May 26, 2025
Liposomal Formulation of Hydroxychloroquine Can Inhibit Autophagy In Vivo.
Journal: Pharmaceutics
Published: September 18, 2024
DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: February 19, 2021
Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 27, 2019
Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use.
Journal: Drug delivery and translational research
Published: September 05, 2019
Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia.
Journal: Pharmaceutical research
Published: March 17, 2019
What Drives Innovation: The Canadian Touch on Liposomal Therapeutics.
Journal: Pharmaceutics
Published: February 23, 2019
Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.
Journal: International journal of molecular sciences
Published: August 09, 2018
Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: March 01, 2018
Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymerase I Inhibitor CX5461.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany)
Published: January 19, 2018
A Perspective - can copper complexes be developed as a novel class of therapeutics?
Journal: Dalton transactions (Cambridge, England : 2003)
Published: July 14, 2017
Last Updated: 09/26/2026